Verve Therapeutics (VERV) AI Stock Analysis

• Market Cap: $987.71M
• Dividend Yield: N/A
• Average Volume (3M): 6.10M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.84
• Revenue Growth: 271.44%
• EPS Growth: 26.65%
• Country: US
• Employees: 274
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.35
• Shares Outstanding: 89,143,234
• 10 Day Avg. Volume: 3,033,951
• 30 Day Avg. Volume: 6,102,299
• PEG Ratio: -0.54
• Price to Book (P/B): 2.02
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.68
• Enterprise Value/Market Cap: 0.97
• Enterprise Value/Revenue: 6.97
• Enterprise Value/Gross Profit: 16.01
• Enterprise Value/Ebitda: -1.11
• 1Y Price Target: $14.25
• Price Target Upside: 28.38% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 9

• Rating: 52 Neutral
• Price Target: $11.50 ▲(3.60%Upside)

Verve Therapeutics' overall stock score reflects strong potential due to the strategic merger with Eli Lilly, which enhances its future prospects in gene editing and genetic medicines. However, the company's current financial performance and valuation remain challenging, with high volatility and overbought technical conditions advising caution.

Positive Factors

Acquisition

The acquisition of Verve Therapeutics by LLY provides significant validation of the company's gene editing capabilities.

Market Potential

The lead indication for VERVE-102, familial hypercholesterolemia (FH), has a high prevalence, creating a large potential market.

Partnership

The definitive agreement by LLY to acquire VERV for up to $1.3 billion reflects a strong collaboration and partnership between the two companies.

Negative Factors

Safety Concerns

The main risk is a safety surprise that derails the Ph2/delays Ph3.

Stock Downgrade

The downgrade of VERV to Market Perform suggests a more cautious outlook on the company's immediate stock performance.

Uncertainty

It's unclear whether VERV's previously guided milestones for the second half of 2025 will occur before the deal closure.

Verve Therapeutics Business Overview & Revenue Model

Company Description

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Verve Therapeutics primarily makes money through the development and commercialization of its gene-editing therapies. The company aims to generate revenue by bringing its proprietary therapies to market following successful clinical trials and regulatory approvals. Additionally, Verve may establish partnerships or collaborations with larger pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties based on the commercial success of the therapies. As a biotechnology firm, Verve's revenue model is highly dependent on the advancement of its therapies through clinical development and the ability to secure strategic partnerships.

Verve Therapeutics Financial Statement Overview

Summary

Verve Therapeutics shows strong revenue growth indicative of potential in its sector. However, profitability remains elusive, as reflected in negative margins and cash flows. The balance sheet is robust, with low leverage and high equity, offering financial stability. The company needs to focus on reducing losses to improve overall financial health.

Income Statement

Verve Therapeutics has shown significant revenue growth with a TTM revenue of $59.61M, up from $32.33M in the previous year, marking an 84.39% increase. However, the company remains unprofitable with a negative net profit margin of -303.69% and a negative EBIT margin of -349.67%. The gross profit margin is relatively strong at 100% due to the absence of cost of goods sold, but the company's high operating losses pose a challenge to achieving profitability.

Balance Sheet

The company's balance sheet reflects a healthy equity ratio of 77.11% in the TTM, indicating a strong reliance on equity over debt. The debt-to-equity ratio is low at 0.14, showcasing low leverage risk. However, the return on equity (ROE) is negative at -38.23%, highlighting the ongoing challenges in converting equity into profits.

Cash Flow

Operating cash flow is negative, with a TTM figure of -$142.46M. The free cash flow to net income ratio is 0.81, indicating that the company is able to generate cash relative to its net losses. Additionally, the free cash flow has slightly improved from the previous year, reflecting efforts in managing expenditures despite ongoing cash outflows.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	32.33M	11.76M	1.94M	0.00	0.00
Gross Profit	32.33M	11.76M	1.94M	-3.38M	-1.33M
EBITDA	-221.91M	-217.67M	-162.88M	-85.53M	-39.30M
Net Income	-198.71M	-200.07M	-157.39M	-118.64M	-45.54M
Balance Sheet
Total Assets	647.39M	752.69M	679.22M	384.12M	78.41M
Cash, Cash Equivalents and Short-Term Investments	524.28M	623.95M	554.81M	360.44M	72.11M
Total Debt	69.98M	74.91M	81.92M	1.96M	125.16M
Total Liabilities	153.99M	153.19M	128.29M	26.77M	142.32M
Stockholders Equity	493.40M	599.50M	550.93M	357.35M	-63.91M
Cash Flow
Free Cash Flow	-161.43M	-158.83M	-135.56M	-82.24M	-38.69M
Operating Cash Flow	-157.69M	-149.55M	-122.33M	-77.88M	-35.27M
Investing Cash Flow	74.88M	27.69M	-155.96M	-239.10M	-51.13M
Financing Cash Flow	49.20M	212.58M	328.96M	377.09M	92.63M

Verve Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VERV, the sentiment is Positive. The current price of 11.1 is below the 20-day moving average (MA) of 11.11, above the 50-day MA of 8.08, and above the 200-day MA of 6.42, indicating a neutral trend. The MACD of 0.72 indicates Positive momentum. The RSI at 75.84 is Negative, neither overbought nor oversold. The STOCH value of 56.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VERV.

Verve Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VERV	52 Neutral	$987.71M	―	-34.26%	―	271.44%	26.65%
TSHA	50 Neutral	$687.82M	―	-159.34%	―	-48.97%	69.32%
IVA	47 Neutral	$448.55M	―	344.74%	―	-47.32%	-26.67%
Sector *	47 Neutral	C$200.31M	-3.37	-23.14%	1.85%	20.75%	-0.36%
OLMA	46 Neutral	$310.63M	―	-41.59%	―	―	0.42%
RNAC	45 Neutral	$316.12M	―	-938.38%	―	38.82%	-645.78%
SANA	33 Underperform	$1.10B	―	-71.44%	―	―	19.94%

Verve Therapeutics Corporate Events

Verve Therapeutics Announces Retention Bonus Program for Executives

Verve Therapeutics announced the establishment of a retention bonus program for its employees, granting significant retention awards to key executives, Allison Dorval and Andrew Ashe, on July 14, 2025. This move is part of the company’s strategic efforts amid pending transactions involving Ridgeway Acquisition Corporation and Eli Lilly and Company, as outlined in the Agreement and Plan of Merger dated June 16, 2025.

The most recent analyst rating on (VERV) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Verve Therapeutics stock, see the VERV Stock Forecast page.

Verve Therapeutics Merges with Eli Lilly in Acquisition

On June 16, 2025, Verve Therapeutics entered into a merger agreement with Eli Lilly, where Lilly will acquire Verve through a tender offer for $10.50 per share, plus a contingent value right of up to $3.00 per share. This acquisition aims to advance Verve’s gene editing programs for cardiovascular disease, with the potential to shift treatment paradigms from chronic care to one-time treatments, enhancing Lilly’s capabilities in cardiometabolic disease and genetic medicines.

The most recent analyst rating on (VERV) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Verve Therapeutics stock, see the VERV Stock Forecast page.

Verve Therapeutics Holds Annual Stockholders Meeting

On June 5, 2025, Verve Therapeutics held its Annual Meeting of Stockholders, where three key proposals were voted on. The stockholders elected Lonnel Coats, Jodie Morrison, and Krishna Yeshwant, M.D. as Class I directors for a three-year term. Additionally, the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025 was ratified, and the compensation for the company’s named executive officers was approved on an advisory basis.

The most recent analyst rating on (VERV) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Verve Therapeutics stock, see the VERV Stock Forecast page.